US Open: indices slightly rebound at the market open; yields continue to climb 📌

22:14 19 āļ˜āļąāļ™āļ§āļēāļ„āļĄ 2024

After yesterday's sharp declines, today's Wall Street opening brings a slight recovery. The main spot indices are gaining 0.60-0.70%, and futures on these indices are rebounding by over 2.00% due to contract rollovers. The dollar is slightly weakening but remains significantly above yesterday's pre-FOMC conference levels. Meanwhile, U.S. bond yields continue to rise. The strong upward trend is particularly evident in 10-year yields, which are approaching 4.56%.

US500

The US500 index lost nearly 3.00% after yesterday's Federal Reserve decision, marking its biggest one-day loss since August this year following the release of NFP data. The chart shows a precarious ascending triangle technical pattern, which typically signals a trend reversal. Yesterday's strong breakout below the lower support line may potentially indicate such a scenario is materializing. If this is the case, continued selling pressure should be expected. On the other hand, bulls are making an effort to defend the support level above 5930 points.

āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļ—āļąāļ™āļ—āļĩāļ§āļąāļ™āļ™āļĩāđ‰ āļŦāļĢāļ·āļ­ āļĨāļ­āļ‡āđƒāļŠāđ‰āļšāļąāļāļŠāļĩāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāđ„āļĢāđ‰āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡

āđ€āļ›āļīāļ”āļšāļąāļāļŠāļĩ āļĨāļ­āļ‡āļšāļąāļāļŠāļĩāđ€āļ”āđ‚āļĄāđˆ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­

Source: xStation 5

Company Highlights

Sangamo Therapeutics (SGMO.US): Shares gained 4.30% after licensing its STAC-BBB capsid technology to Astellas Pharma for $20M upfront, up to $1.3B in milestones, and royalties, targeting neurological diseases.

 

Accenture (ACN.US) gains 0.70% as FQ1 results beat expectations, FY2025 revenue growth outlook was raised to 4%-7%, and plans to return $8.3B to shareholders boosted confidence.

Micron Technology (MU.US) dips 15% due to weak FQ2 guidance, with earnings ($1.33–$1.53/share) and revenue ($7.7B–$8.1B) below consensus, despite optimism for AI-driven growth.

 

Vertex Pharmaceuticals (VRTX.US) dropped 11.85% after trial results for its pain drug suzetrigine showed similar efficacy to placebo (-1.98 vs. -2.02), raising concerns despite plans for pivotal trials.

 

 

āļŦāļļāđ‰āļ™:
āļāļĨāļąāļšāđ„āļ›

āļ‚āđˆāļēāļ§āđƒāļ™āļ•āļĨāļēāļ”āļāļēāļĢāđ€āļ‡āļīāļ™

17.09.2025
08:58

āļ‚āđˆāļēāļ§āđ€āļ”āđˆāļ™āļ§āļąāļ™āļ™āļĩāđ‰: EURUSD āļžāļļāđˆāļ‡ 0.8% āļāđˆāļ­āļ™ Fed 📈 āļ™āđ‰āļģāļĄāļąāļ™āļ‚āļķāđ‰āļ™ āļŦāļļāđ‰āļ™āļŠāļŦāļĢāļąāļāļŊ āđāļāļ§āđˆāļ‡āđƒāļāļĨāđ‰āļŠāļđāļ‡āļŠāļļāļ”

āđ€āļ‹āļŠāļŠāļąāļ™āļĒāļļāđ‚āļĢāļ›āļ–āļđāļāļ„āļĢāļ­āļšāļ‡āļģāđ‚āļ”āļĒāđāļĢāļ‡āļ‚āļēāļĒ DAX āļĨāļ”āļĨāļ‡āđ€āļāļ·āļ­āļš 1.8% āļ™āļģāđ‚āļ”āļĒāļŦāļļāđ‰āļ™āļ›āļĢāļ°āļāļąāļ™āđāļĨāļ°āļ˜āļ™āļēāļ„āļēāļĢ āļ‚āđˆāļēāļ§āļāļŽāļŦāļĄāļēāļĒāļ āļēāļĐāļĩāļ­āļīāļ•āļēāļĨāļĩāļ­āļēāļˆāļāļĢāļ°āļ—āļšāļœāļĨāļāļģāđ„āļĢāļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™āļāļēāļĢāđ€āļ‡āļīāļ™ āļ§āļ­āļĨāļĨāđŒāļŠāļ•āļĢāļĩāļ—āļĢāļ°āļĄāļąāļ”āļĢāļ°āļ§āļąāļ‡...

08:57

US500 āļŠāļđāļāđ€āļŠāļĩāļĒāđ‚āļĄāđ€āļĄāļ™āļ•āļąāļĄ ðŸ—― Uranium Energy Corp āļĨāļ”āļĨāļ‡ 4% āļˆāļēāļāļĢāļ°āļ”āļąāļšāļŠāļđāļ‡āļŠāļļāļ”āđƒāļ™āļ›āļĢāļ°āļ§āļąāļ•āļīāļĻāļēāļŠāļ•āļĢāđŒ

āļ•āļĨāļēāļ”āļŦāļļāđ‰āļ™āļŠāļŦāļĢāļąāļāļŊ āļ›āļĢāļąāļšāļ•āļąāļ§āļ­āđˆāļ­āļ™āđāļĢāļ‡āđ€āļĨāđ‡āļāļ™āđ‰āļ­āļĒāļŦāļĨāļąāļ‡āđ€āļ›āļīāļ”āļ•āļĨāļēāļ”āđƒāļ™āļ§āļ­āļĨāļĨāđŒāļŠāļ•āļĢāļĩāļ— āļ āļēāļ„āļ—āļĩāđˆāđāļ‚āđ‡āļ‡āđāļāļĢāđˆāļ‡āļ—āļĩāđˆāļŠāļļāļ”āļ„āļ·āļ­ āļ™āđ‰āļģāļĄāļąāļ™āđāļĨāļ°āļāđŠāļēāļ‹ āļ‹āļķāđˆāļ‡āļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļ·āđˆāļ­āļĄāļąāđˆāļ™āļˆāļēāļāļāļēāļĢāļ„āļēāļ”āļāļēāļĢāļ“āđŒāļĨāļ”āļ”āļ­āļāđ€āļšāļĩāđ‰āļĒ āļ•āļąāļ§āđ€āļĨāļ‚āđ€āļĻāļĢāļĐāļāļāļīāļˆāļŠāļŦāļĢāļąāļāļŊ...

08:56

āļĢāļēāļ„āļēāļ„āļēāđ€āļ„āļē āļĨāļ”āļĨāļ‡ 3% āđāļĄāđ‰āļ›āļĢāļīāļĄāļēāļ“āļŠāļ•āđ‡āļ­āļ ICE āļ•āđˆāļģāļŠāļļāļ”āļ•āļąāđ‰āļ‡āđāļ•āđˆāđ€āļ”āļ·āļ­āļ™āļžāļĪāļĐāļ āļēāļ„āļĄ ðŸ“‰

āļŸāļīāļ§āđ€āļˆāļ­āļĢāđŒāļŠāļ”āļąāļŠāļ™āļĩ āļ„āļēāđ€āļ„āļē āļ§āļąāļ™āļ™āļĩāđ‰āļĨāļ”āļĨāļ‡āļĄāļēāļāļāļ§āđˆāļē 3% āļŦāļĨāļąāļ‡āļˆāļēāļāļ›āļĢāļąāļšāļ•āļąāļ§āļ‚āļķāđ‰āļ™āđƒāļ™āļ§āļąāļ™āļˆāļąāļ™āļ—āļĢāđŒāđāļ•āļ°āļĢāļ°āļ”āļąāļšāļŠāļđāļ‡āļŠāļļāļ”āđƒāļ™āļĢāļ­āļšāļŠāļąāļ›āļ”āļēāļŦāđŒāļāļ§āđˆāļē āđ† āđ„āļ”āđ‰āļĢāļąāļšāđāļĢāļ‡āļŦāļ™āļļāļ™āļˆāļēāļāļ›āļąāļāļŦāļēāļŠāļ āļēāļžāļ­āļēāļāļēāļĻāđƒāļ™āđāļ­āļŸāļĢāļīāļāļēāļ•āļ°āļ§āļąāļ™āļ•āļāļ—āļĩāđˆāļ„āļļāļāļ„āļēāļĄāļœāļĨāļœāļĨāļīāļ•āđāļĨāļ°āļˆāļģāļāļąāļ”āļ­āļļāļ›āļ—āļēāļ™āļĢāļ°āļĒāļ°āļŠāļąāđ‰āļ™ āđƒāļ™...

āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ•āļĨāļēāļ”āļžāļĢāđ‰āļ­āļĄāļĨāļđāļāļ„āđ‰āļēāļ‚āļ­āļ‡ XTB Group āļāļ§āđˆāļē 1 700 000 āļĢāļēāļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ